Jenscare Scientific Co., Ltd. announce that recently, the results of multicenter clinical trial of LuX-Valve Plus transvascular tricuspid valve replacement system ("TRAVEL II") were officially published at the 2023 Transcatheter Cardiovascular Therapeutics Conference ("TCT") by Academician Ge Junbo from Zhongshan Hospital affiliated to Fudan University. TRAVEL II is a prospective, multicenter and single-arm clinical trial, which primarily evaluates the long-term safety and efficacy of LuX-Valve Plus in the application on patients
with severe tricuspid regurgitation. The TRAVEL II clinical trial enrolled 96 patients from 15 centers in China. The primary endpoint of the one-month clinical data released was the
composite event rate within 30-days after the procedures. As of the date of this announcement, nearly 500 implantation cases have been completed worldwide for transcatheter tricuspid valve replacement system products independently developed by the Company, and the longest follow-up record was over 5 years. The Company will continue to promote the commercialization of its products in China, Europe, the U.S. and the Asia-Pacific region.